VIRxSYS Corporation announced today the presentation of a new analysis of safety data from Phase I and Phase II studies of VRX496, their proprietary HIV-based lentiviral vector gene delivery system, at the American Society for Microbiology's 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago.
MolMed’s strategic partner Takara Bio Inc. (Japan) is developing M3TK for the Asian markets. MolMedの重要な協力国タカラBio社(日本)は、アジアの市場のためにM3TKを開発しています。
ARENEGYR, a novel VTA, in Phase II in several indications including colorectal cancer; 結腸直腸ガンを含むいくつかの徴候のPhase IIのARENEGYR、新しいVTA;
8. and TK, a cell-based therapy enabling safe haematopoietic stem cell trans plantation (HSCT) from partially compatible bone marrow donors, that completed Phase I/II. そして、TK(部分的に互換の骨髄提供者から安全な血液生成幹細胞移植 (HSCT)を可能にしている細胞ベースの治療法)はPhase I/IIをとても完了しました。
9. MolMed’s clinical pipeline is backed by a broad portfolio of therapeutic candidates. MolMedの臨床パイプラインは、治療的な候補の幅広いポートフォリオによって後援します。
“The data we are presenting this week furthers our belief that VRX496, our lentiviral vector- based gene delivery system, is safe,” said Riku Rautsola, PhD, President and CEO of VIRxSY S. “We have administered as many as 78 billion transduced cells to patients without any treat ment associated adverse events. The results presented here are the first safety data available on the human administration of lentiviral vectors. We are proud that we can share such important n ews at this prestigious conference.” VIRxSYS will be presenting at the poster session on Wednesday, September 18 at 12:15 pm. Successful results of a Phase I study of VRX496 have previously been reported (Levine et al. P NAS 2006). In ongoing Phase II clinical trials for VRX496, VIRxSYS has treated a total of 24 pat e bolus infusions ranging from 10 to 30 billion cells per dose. To date, this trial has demonstra ted the safety and tolerability of multiple infusions and larger bolus infusions. These patients a re currently being monitored to determine the optimal treatment regimen for patients. About VIRxSYS Founded in 1998, VIRxSYS is a private biotechnology company that focuses on the development of a n ovel lentiviral vector platform technology for the treatment of serious diseases such as HIV/AIDS, ca rdiovascular disease and hemophilia. The Company has exclusively licensed its patented, proprietary t echnology platform from The Johns Hopkins University (JHU) in Baltimore, Maryland where the origin al research was conducted. The Company also has been issued additional patents relating to the appl ication and manufacture of the technology. More information regarding VIRxSYS can be found at www. virxsys.com. Details for the Phase II study may be found at the NIH clinical trials website at clinicalt rials.gov/show/NCT00131560. A full press kit is available by emailing: [email protected].